Company

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer's Treatment Access
Boao Lecheng pilot zoneEisai

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer’s Treatment Access

Eisai Co., Ltd. (TYO: 4523) announced that China's first prescription for the subcutaneous autoinjector formulation of Leqembi (lecanemab) was issued at the Hainan Hospital of Ruijin Hospital Affiliated to Shanghai…

ZEGFROVY (sunvozertinib) Officially Launches in the U.S. as Dizal and AstraZeneca Bring First Oral EGFR TKI Option to Pretreated Exon 20 Insertion NSCLC

ZEGFROVY (sunvozertinib) Officially Launches in the U.S. as Dizal and AstraZeneca Bring First Oral EGFR TKI Option to Pretreated Exon 20 Insertion NSCLC

Ipsen Raises Full‑Year 2026 Guidance as 9M Sales Surge 23.0% to EUR 3.36 Billion – Rare Disease Doubles and Oncology Accelerates Ahead of Somatuline Generic Entry

Ipsen Raises Full‑Year 2026 Guidance as 9M Sales Surge 23.0% to EUR 3.36 Billion – Rare Disease Doubles and Oncology Accelerates Ahead of Somatuline Generic Entry

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Pfizer-Astellas' PADCEV Wins FDA Approval for Perioperative Bladder Cancer
ADC / XDCAstellas Pharma

Pfizer-Astellas’ PADCEV Wins FDA Approval for Perioperative Bladder Cancer

GenSci's GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials
Changchun High & New Technology IndustriesClinical trial approval / initiation

GenSci’s GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials

Jiuzhou Pharmaceutical Wins Tentative FDA Approval for Generic Janumet XR
Generic drugsJiuzhou Pharmaceutical

Jiuzhou Pharmaceutical Wins Tentative FDA Approval for Generic Janumet XR

Hengrui's Ivarmacitinib Wins NMPA Nod for Vitiligo Clinical Trials
Auto-immuneClinical trial approval / initiation

Hengrui’s Ivarmacitinib Wins NMPA Nod for Vitiligo Clinical Trials

Show More